MoonLake Immunotherapeutics (MLTX) Projected to Post Quarterly Earnings on Wednesday

MoonLake Immunotherapeutics (NASDAQ:MLTX) will likely be announcing its Q4 2025 results before the market opens on Wednesday, February 25th. Analysts expect the company to announce earnings of ($0.97) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 9:30 AM ET.

MoonLake Immunotherapeutics Stock Up 11.1%

Shares of MLTX opened at $17.52 on Wednesday. The company has a debt-to-equity ratio of 0.25, a quick ratio of 8.50 and a current ratio of 8.50. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -5.28 and a beta of 1.21. MoonLake Immunotherapeutics has a 52 week low of $5.95 and a 52 week high of $62.75. The stock has a fifty day moving average of $15.00 and a 200-day moving average of $24.82.

Analyst Ratings Changes

Several equities analysts have issued reports on the stock. BTIG Research restated a “buy” rating and issued a $24.00 price target on shares of MoonLake Immunotherapeutics in a research report on Monday, February 9th. UBS Group set a $24.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday, January 9th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Tuesday, February 3rd. Citigroup lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating in a research report on Wednesday, October 29th. Finally, The Goldman Sachs Group lowered MoonLake Immunotherapeutics from a “neutral” rating to a “sell” rating and increased their price target for the stock from $8.00 to $10.00 in a report on Wednesday, January 14th. Seven analysts have rated the stock with a Buy rating, four have assigned a Hold rating and five have issued a Sell rating to the stock. According to data from MarketBeat.com, MoonLake Immunotherapeutics currently has a consensus rating of “Hold” and an average price target of $25.77.

Insider Buying and Selling

In related news, insider Kristian Reich sold 130,000 shares of MoonLake Immunotherapeutics stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the transaction, the insider owned 72,908 shares of the company’s stock, valued at $1,099,452.64. The trade was a 64.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Da Silva Jorge Santos sold 130,000 shares of the stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $15.08, for a total transaction of $1,960,400.00. Following the completion of the sale, the chief executive officer owned 2,948,577 shares of the company’s stock, valued at approximately $44,464,541.16. This represents a 4.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 402,908 shares of company stock worth $5,987,162 in the last 90 days. Corporate insiders own 12.05% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Wells Fargo & Company MN increased its holdings in MoonLake Immunotherapeutics by 92.0% during the 4th quarter. Wells Fargo & Company MN now owns 10,000 shares of the company’s stock worth $132,000 after acquiring an additional 4,792 shares during the period. Brooklyn Investment Group purchased a new position in shares of MoonLake Immunotherapeutics during the fourth quarter worth about $204,000. Campbell & CO Investment Adviser LLC bought a new position in shares of MoonLake Immunotherapeutics in the fourth quarter worth approximately $177,000. Quarry LP lifted its holdings in shares of MoonLake Immunotherapeutics by 400.1% during the 3rd quarter. Quarry LP now owns 9,001 shares of the company’s stock worth $65,000 after acquiring an additional 7,201 shares during the last quarter. Finally, Bellevue Group AG grew its position in MoonLake Immunotherapeutics by 1,068.4% in the third quarter. Bellevue Group AG now owns 35,052 shares of the company’s stock worth $251,000 after acquiring an additional 32,052 shares in the last quarter. 93.85% of the stock is currently owned by hedge funds and other institutional investors.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immunomodulatory therapies for autoimmune and inflammatory diseases. The company leverages a proprietary platform designed to selectively modulate key immune cell populations, aiming to restore immune balance and reduce tissue damage with targeted biologic candidates.

Its lead asset, MLTX101, is a recombinant immune cell modulator in clinical development for myositis, including inclusion body myositis and dermatomyositis.